Back to Search
Start Over
Pharmacokinetics of dabigatran etexilate and rivaroxaban in patients with short bowel syndrome requiring parenteral nutrition: The PDER PAN study
- Source :
- Thrombosis research, 160, 76-82. Elsevier Limited
- Publication Year :
- 2017
- Publisher :
- Elsevier BV, 2017.
-
Abstract
- Background and aims: Patients on parenteral nutrition for short bowel syndrome (SBS) have a high risk of thrombotic complications and are often treated with parenteral anticoagulation. Direct oral anticoagulants are absorbed proximally in the digestive tract and may represent alternative regimens in selected SBS patients. In our pilot study, we provided pharmacokinetics parameters of dabigatran etexilate and rivaroxaban in this setting and compared peak (Cmax), trough (Ctrough) concentrations, and areas-under-the-concentration-time-curve (AUC(0) (-) (t)) to reference values retrieved from phase I-III studies. Methods: We enrolled 6 adults with a remaining small bowel length
- Subjects :
- Adult
Male
Short Bowel Syndrome
Parenteral Nutrition
medicine.medical_specialty
Cmax
030204 cardiovascular system & hematology
Gastroenterology
Antithrombins
Dabigatran
03 medical and health sciences
0302 clinical medicine
Rivaroxaban
Pharmacokinetics
Internal medicine
medicine
Humans
030212 general & internal medicine
Dosing
Aged
business.industry
Hematology
Middle Aged
Short bowel syndrome
medicine.disease
Crossover study
Parenteral nutrition
Anesthesia
Female
business
medicine.drug
Subjects
Details
- ISSN :
- 00493848
- Volume :
- 160
- Database :
- OpenAIRE
- Journal :
- Thrombosis Research
- Accession number :
- edsair.doi.dedup.....cacd9e62ba2ba623ddeb2c9aad3fceb2